Level D· Scientific groundwork from lab and animal studiesLaboratory StudyEurope PMC

Biphasic organo-bioceramic fibrous composite as a biomimetic extracellular matrix for bone tissue regeneration

Kumar S., Stokes JA., Dean D., Rogers C., Nyairo E., Thomas V.

Laboratory Study, published in Front Biosci (Elite Ed) (2017) — summary generated from the PubMed abstract.

Open my reading list
Level D· Scientific groundwork from lab and animal studiesEvidence level of this study

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Laboratory Study
Journal
Front Biosci (Elite Ed) (2017)
Reported sample size
—
Source database
Europe PMC
PMID
28199184
PMCID
PMC5548663
DOI
10.2741/e795
Citations
3

Abstract (original English)

In bone tissue engineering, the organo-ceramic composite, electrospun polycaprolactone/hydroxyapatite (PCL/HA) scaffold has the potential to support cell proliferation, migration, differentiation, and homeostasis. Here, we report the effect of PCL/HA scaffold in tissue regeneration using human mesenchymal stem cells (hMSCs). We characterized the scaffold by fourier transform infrared spectroscopy (FTIR), differential scanning calorimetry (DSC), scanning electron microscope (SEM) and assessed its biocompatibility. PCL/HA composite is superior as a scaffold compared to PCL alone. Furthermore, increasing HA content (5-10%) was more efficacious in supporting cell-scaffold attachment, expression of ECM molecules and proliferation. These results suggest that PCL/HA is useful as a scaffold for tissue regeneration.

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.
  • • This is preclinical work; animal or laboratory results cannot be applied to humans.

Evidence level

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

How we grade evidence
Bone and BonesExtracellular MatrixMesenchymal Stem CellsHumansDurapatitePolyestersMicroscopy, Electron, ScanningCalorimetry, Differential ScanningSpectroscopy, Fourier Transform InfraredTissue Engineering

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.